scholarly journals A rare cause of pericardial effusion and ascites: POEMS syndrome

2017 ◽  
Vol 9 (4) ◽  
Author(s):  
Bilal Katipoglu ◽  
Zeynep Katipoğlu ◽  
Ihsan Ates ◽  
Gokhan Yirgin ◽  
Burak Furkan Demir ◽  
...  
Keyword(s):  
Differential Diagnosis ◽  
Case Report ◽  
Pericardial Effusion ◽  
Paraneoplastic Syndrome ◽  
Volume Overload ◽  
Poems Syndrome ◽  
Initial Presentation ◽  
Multisystem Involvement ◽  
Extravascular Volume

POEMS syndrome is an important paraneoplastic syndrome associated with multisystem involvement. Extravascular volume overload like pericardial effusion and ascites has a broad differential diagnosis. In addition, it may be initial presentation of disease. For that reason, this case report is highlight to warn of different forms of presentation of poems syndrome.

scholarly journals Lenalidomide and Dexamethasone for a Patient of POEMS Syndrome Presenting with Massive Ascites

2014 ◽  
Vol 2014 ◽  
pp. 1-3 ◽  
Author(s):  
Shuji Ueda ◽  
Sayoko Yonemoto ◽  
Kazumasa Oka ◽  
Naohiko Fujii ◽  
Keiichi Nakata ◽  
...  
Keyword(s):  
Pleural Effusion ◽  
Low Dose ◽  
Renal Involvement ◽  
Volume Overload ◽  
Poems Syndrome ◽  
Refractory Ascites ◽  
Multisystem Disorder ◽  
Massive Ascites ◽  
Skin Changes ◽  
Extravascular Volume

POEMS syndrome is a multisystem disorder characterized by polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes. POEMS syndrome is a rare cause of refractory ascites. We report the case of a patient with POEMS syndrome presenting with massive ascites who was treated with very-low-dose lenalidomide and dexamethasone. A 57-year-old Japanese man was admitted to our hospital with pleural effusion, massive ascites, and leg edema. The diagnosis of POEMS syndrome was made based on the combination of the following findings: peripheral neuropathy, organomegaly, endocrinopathy, serum monoclonal protein elevation, skin changes, plasma VEGF elevation, and evidence of extravascular volume overload. Renal dysfunction induced by biopsy-proven renal involvement of POEMS syndrome was observed. Massive ascites of the patient dramatically diminished with long-time treatment of very-low-dose lenalidomide and dexamethasone. Lenalidomide seems to be a very promising therapy for POEMS syndrome presenting with extravascular volume overload such as edema, pleural effusion, and ascites. Very-low-dose lenalidomide might be effective especially for the patients with POEMS-related nephropathy.

scholarly journals Combination of melphalan and dexamethasone for patients with newly diagnosed POEMS syndrome

Blood ◽  
2011 ◽  
Vol 117 (24) ◽  
pp. 6445-6449 ◽  
Author(s):  
Jian Li ◽  
Wei Zhang ◽  
Li Jiao ◽  
Ming-Hui Duan ◽  
Hong-Zhi Guan ◽  
...  
Keyword(s):  
Volume Overload ◽  
Poems Syndrome ◽  
Vascular Endothelial ◽  
Newly Diagnosed ◽  
Plasma Cell Disorder ◽  
Low Toxicity ◽  
Grade 3 ◽  
Extravascular Volume ◽  
A Prospective Study ◽  
Endothelial Growth Factor

Abstract POEMS syndrome is a rare clonal plasma cell disorder without standard treatment. Based on the efficacy and low toxicity of a combination of melphalan and dexamethasone (MDex) for light chain amyloidosis, we conducted a prospective study of MDex treatment for patients with newly diagnosed POEMS syndrome. Thirty-one patients (19 men) were enrolled and the median age at the time of diagnosis was 44 years (range, 32-68 years). All patients received 12 cycles of MDex treatment. Twenty-five patients (80.6%) achieved hematologic response including 12 (38.7%) complete remission and 13 (41.9%) partial remission. Of all 31 patients, the neurologic response rate was 100%, assessed by overall neuropathy limitation scale (ONLS). The initial neurologic response was observed in 24 patients (77.4%) at 3 months after treatment and the median time to maximal neurologic response was 12 months (range, 3-15 months). Moreover, MDex substantially improved the level of serum vascular endothelial growth factor and relieved organomegaly, extravascular volume overload, and pulmonary hypertension. Only 6 patients (19.3%) suffered from grade 3 adverse events during treatment. All patients are alive and free of neurologic relapse after the median follow-up time of 21 months. Therefore, MDex is an effective and well-tolerated treatment option for patients with newly diagnosed POEMS syndrome.

scholarly journals Poems syndrome. Differential diagnosis in a refractory polyneuropathy. A case report

2015 ◽  
Vol 357 ◽  
pp. e340
Author(s):  
D. Vilaça Egídio Souza Lima ◽  
D. Dayane Cordeiro Martins ◽  
T. Michel Dos Santos ◽  
J. Azevedo Santos Pacheco ◽  
A. Aguiar Souza Costa ◽  
...  
Keyword(s):  
Differential Diagnosis ◽  
Case Report ◽  
Poems Syndrome

Acute pulmonary edema as the initial presentation of a pheochromocytoma: case report

2013 ◽  
Author(s):  
Eduarda Resende ◽  
Maritza Sa ◽  
Margarida Ferreira ◽  
Silvestre Abreu
Keyword(s):  
Case Report ◽  
Pulmonary Edema ◽  
Initial Presentation ◽  
Acute Pulmonary Edema
Sign in / Sign up

Export Citation Format

Share Document